Although previous studies had indicated that the CD8α- and CD8α+ subtypes of murine dendritic cells (DCs) differ in immediate origin, a recent study found that intravenous transfer of CD8α- DCs led to CD8α+ DCs in the spleen several days later, suggesting a direct precursor-product relationship. We have repeated these experiments with a balance sheet approach. We find that though a few CD8α+ DCs can be generated in such experiments, this is a rare event and could be the result of a contaminant precursor. Most of the immediate precursors of CD8α+ DCs are cells that lack the phenotype of a recognizable DC. CD8α- DCs and CD8α+ DCs are not precursor-product related, though these sublineages may be connected further upstream.

The CD8α+ and CD8α- subsets of dendritic cells (DCs) from mouse spleen are of special interest because, as freshly isolated cells, they differ in functional characteristics.1  However, the developmental origin of these DC subtypes and their relationship to each other has been controversial. The original view that splenic CD8α+ DCs were of lymphoid origin and that splenic CD8α- DCs were of myeloid origin has been shown to be incorrect.2,3  Differences in the cytokine and transcription factor requirements suggest that the developmental pathways involved differ.4-8  Culture of purified splenic CD8α+ DCs or splenic CD8α- DCs has failed to show any transformation from one to the other,9  though evidence indicates that CD8α can be induced to at least moderate levels on some DC subtypes.10,11  An in vivo kinetic study, using continuous 5-bromodeoxyuridine (BrdU) labeling, showed no sign of a precursor-product relationship between CD8α- and CD8α+ DCs.9 

In direct conflict with this is the conclusion in a recent paper by Martinez del Hoyo et al.12  They isolated CD8α- DCs, transferred them intravenously into a Ly5-disparate, nonirradiated recipient, and found 3 to 4 days later CD8α+ DCs of donor origin. They concluded that CD8α+ DCs normally originate from CD8α- DCs—the 2 are merely maturation stages of the same lineage. In view of the conflict, we have now carried out similar experiments. Although we did obtain some CD8α+ DCs on transfer of a CD8α- DC preparation, recoveries were extremely low, and we argue this is an uncommon event that might be attributed to a contaminant precursor. We find that most of the immediate precursors of CD8α+ DCs are cells lacking normal DC characteristics.

Mice

C57BL/6J WEHI (Ly5.2) mice 6 to 8 weeks of age were used as donors, and C57BL/6 Pep3b mice (Ly5.1) of a similar age range were used as nonirradiated recipients.

Preparation of CD8α- DCs

The method used, described previously,13  was similar to that of Martinez del Hoyo et al,12  except that fluorescence-activated cell sorting (FACS) rather than immunomagnetic microbead selection was used in the final separation. Samples of the original spleen suspension (after red cell and dead cell removal14 ) and of cells at all stages of the procedure were retained for counting and assay of precursor activity. Briefly, spleens were digested for 20 minutes at room temperature with collagenase-DNAase then were treated with ethylenediaminetetraacetic acid (EDTA). All subsequent procedures were performed at 0°C to 4°C in an EDTA-salt solution. Light-density cells, 5% of the total nucleated spleen cells, were selected by centrifugation in a 1.077 g/cm3 Nycodenz medium. Non-DC and plasmacytoid cells were depleted by incubation with rat monoclonal antibody (mAb) to CD3, CD45R (B220), Thy-1, Gr-1, and erythrocytes (TER-119), and they were removed using antirat immunoglobulin immunomagnetic beads. Autofluorescent cells were removed by rapid presorting of the unlabeled preparation or by gating out at the time of sorting.13  Control experiments indicated an average 50%, and never more than 70%, of DCs were lost during these enrichment procedures. The resultant DC-enriched preparation, approximately 2% of the original spleen, was usually stained for CD11c (N418-fluorescein), major histocompatibility complex 2 (MHC 2) (M5/114-Alexa 594), and CD8α (YTS169.4-Cy5) and for the CD11chiMHC 2hiCD8α- fraction selected. Alternatively, the DC-enriched preparation, 50% to 60% pure and representing approximately 2% of the original spleen, was usually stained for one of these markers, and cells with negative, medium, and high fluorescence above background were sorted. Reanalysis of the CD11chiMHC 2hiCD8α- fraction gave a purity of 99%, with no CD8α+ DCs detected.

Assay for immediate precursors of CD8α+ DCs

The assay used was based on that used by Martinez del Hoyo et al.12  Samples of various DC-enrichment fractions were transferred intravenously (1-10 × 106 cells per mouse) into 2 or more nonirradiated Ly5.1 recipients. Three days later, the spleens of recipient mice were pooled. DCs were then extracted and enriched by density separation and immunomagnetic bead depletion, as described,13  to allow clean analysis of donor-derived DCs. Cells were counted and stained for donor-type Ly5.2 (ALI-4A2-biotin with streptavidin-phycoerythrin or streptavidin-Alexa 594 second stage), for CD11c (N418-fluorescein), for CD8α (YTS169.4-Cy5), and in some experiments for CD205 (NLDC-145). The number of donor-derived CD8α+ DCs produced per cell transferred was then determined as a measure of precursor activity.

Generation of CD8α+ DCs from the CD11chiMHC 2hiCD8α- DC fraction

We first attempted to repeat the experiment whereby the transfer of purified CD8α- splenic DCs produced CD8α+ DCs.12  However, to obtain high purity and to segregate different levels of marker expression, we used FACS rather than immunomagnetic particle separation in the final separation of CD8α- DCs. We additionally selected cells bearing relatively high levels of MHC 2, therefore defining more tightly the DC population. Purity was close to 99% on reanalysis, so approximately 1% of the preparation represented possible contaminants. These cells (3-5 × 106) were then transferred intravenously into nonirradiated Ly5.1 recipients. A DC-enriched preparation was made 3.5 days later from the pooled recipient spleens, and the donor-derived (Ly5.2+) cells were gated and analyzed.

In 3 of 7 transfer experiments, donor-derived DCs were detected in the recipient spleens. From 5% to 30% of these donor-derived DCs were CD8α+ (Figure 1) and DEC-205+, whereas the rest remained CD8α- or stained at only low levels for CD8α. Similar results were obtained at days 2 and 4. Thus, we sometimes did see the generation of CD8α+ DCs from a CD8α- DC fraction, though, in contrast to the previous study,12  only a minority showed the acquisition of CD8. Given that most splenic DCs turn over in 3 days,9  most donor-derived DCs should have been CD8α+ if they originated from the CD8α- DC subset.

Figure 1.

Characterization of donor-derived DCs after transfer of purified CD8α- DCs. Splenic CD8α-CD11chiMHC 2hi DCs were isolated and sorted from Ly5.2 mice and transferred intravenously into nonirradiated Ly5.1 recipients (5 × 106 per mouse). After 3.5 days, DCs were isolated from the pooled recipient spleens, and Ly5.2+CD11c+ DCs were analyzed for CD8α expression. Histograms indicate Ly5.2 gated cells either unstained (gray line) or stained (black line) for CD8α, with the vertical line indicating the cutoff for levels of CD8α on CD8αhi DCs. Of 7 transfer experiments, 4 gave no detectable donor-derived DCs, whereas 3 gave donor-derived DCs containing 5% to 33% CD8α+ DCs. The experiment presented is the one showing the highest donor cell recoveries and the highest proportion of Ly5.2+CD8α+ DCs.

Figure 1.

Characterization of donor-derived DCs after transfer of purified CD8α- DCs. Splenic CD8α-CD11chiMHC 2hi DCs were isolated and sorted from Ly5.2 mice and transferred intravenously into nonirradiated Ly5.1 recipients (5 × 106 per mouse). After 3.5 days, DCs were isolated from the pooled recipient spleens, and Ly5.2+CD11c+ DCs were analyzed for CD8α expression. Histograms indicate Ly5.2 gated cells either unstained (gray line) or stained (black line) for CD8α, with the vertical line indicating the cutoff for levels of CD8α on CD8αhi DCs. Of 7 transfer experiments, 4 gave no detectable donor-derived DCs, whereas 3 gave donor-derived DCs containing 5% to 33% CD8α+ DCs. The experiment presented is the one showing the highest donor cell recoveries and the highest proportion of Ly5.2+CD8α+ DCs.

Close modal

Recovery of DCs on transfer of the CD8α- DC fraction

In addition to the low proportion of DCs that became CD8α+, a disturbing aspect of the experiment was the low overall recovery rate of the transferred DCs in the spleens of the recipient mice (Table 1). This was true at all time points studied. The highest recovery rate measured in these experiments was 0.33% of the CD8α- DCs transferred, of which only approximately one quarter were CD8α+ DCs (Table 1). Even allowing for a 50% loss of DCs in the enrichment procedure preceding analysis, at most 0.16% of the transferred DCs produced CD8α+ DCs in the recipient spleens.

Table 1.

Recovery of transferred cells


Transferred cells

Recovery rate, %
All donor-derived cells   0.33  
Donor-derived DCs   0.24  
Donor-derived CD8α+ DCs
 
0.08
 

Transferred cells

Recovery rate, %
All donor-derived cells   0.33  
Donor-derived DCs   0.24  
Donor-derived CD8α+ DCs
 
0.08
 

Values are from the experiment in Figure 1 and show the highest recoveries obtained

This is in line with the reported values of Martinez del Hoyo et al,12  from which it can be calculated that only 0.3% of the transferred cells were recovered as CD8α+ DCs. Because this is within the contaminant level of the transferred CD8α- DCs, it was not proven that it was the CD8α- DCs themselves that produced the CD8α+ DCs.

Distribution of the immediate precursors of CD8α+ DCs during DC enrichment

It could still be argued that this observed production of CD8α+ DCs, though derived from only 0.3% of the CD8α- DC fraction injected, was representative of the other 99.7% transferred but lost. If all the immediate precursors of CD8α+ DCs were indeed CD8α- DCs, such precursor activity, as measured by the ability to produce CD8α+ DCs in the spleen 3 days after transfer, should separate with CD8α- DCs and therefore be more than 100-fold enriched in a pure CD8α- DC fraction. The distribution of such immediate CD8α+ DC precursor activity in fractions sampled during the steps of DC isolation was therefore determined after intravenous transfer of a counted number of cells. Precursor activity was determined as specific activity (donor-derived CD8α+ DCs per recipient spleen per 106 donor cells transferred) and then calculated as total activity (specific activity × 10-6 multiplied by the number of cells in each separation fraction from one donor spleen) (Table 2). Specific activity allows a measure of precursor enrichment, and total activity allows a measure of precursor recovery.

Table 2.

Immediate precursors of CD8α+ DCs are not all recovered in the DC-enriched fractions



Immediate CD8+ DC precursor activity
Fraction
Specific activity per 106 donor cells
Total activity per donor spleen
Spleen suspension   31 ± 6   5490 ± 910  
Light-density cells   169 ± 93   1660 ± 260  
Enriched DCs, immunomagnetic bead depletion   254 ± 41   730 ± 90  
Enriched DCs, autofluorescent cells removed   162 ± 67   630 ± 150  
Autofluorescent cells   39   10  
Enriched DCs, CD11c labeled   160 ± 68   620 ± 180  
Enriched DCs, CD8α labeled
 
161 ± 70
 
620 ± 110
 


Immediate CD8+ DC precursor activity
Fraction
Specific activity per 106 donor cells
Total activity per donor spleen
Spleen suspension   31 ± 6   5490 ± 910  
Light-density cells   169 ± 93   1660 ± 260  
Enriched DCs, immunomagnetic bead depletion   254 ± 41   730 ± 90  
Enriched DCs, autofluorescent cells removed   162 ± 67   630 ± 150  
Autofluorescent cells   39   10  
Enriched DCs, CD11c labeled   160 ± 68   620 ± 180  
Enriched DCs, CD8α labeled
 
161 ± 70
 
620 ± 110
 

Successive stages in the isolation of DCs from C57BL/6 mouse spleen (Ly5.2) were sampled and assayed for the ability to produce CD8α+ DCs in the spleens of nonirradiated recipient Ly5.1 mice 3.5 days after intravenous transfer. Immediate CD8α+ DC precursor activity is expressed on a specific activity basis (Ly5.2+CD8α+CD11c+ DCs per recipient spleen per 106 cells transferred) or on a total activity per original donor spleen basis (calculated as Ly5.2+CD8α+CD11c+ DCs per recipient spleen per cell transferred multiplied by the total cells obtained in each fraction from 1 donor spleen). On average, 5% of the original viable nucleated spleen cells were found in the light-density fraction and 2% were found in the DC-enriched fraction. Autofluorescent cells constituted on average 10% of the DC-enriched fraction. Results are the means from 4 experiments, with the error bars indicating ranges

To gauge the enrichment and recovery of CD8α+ DC precursors concomitant with CD8α- DC enrichment, the total CD8α+ DC precursor potential of a spleen was first determined. A suspension of spleen cells, with dead cells and erythrocytes removed, was counted and injected intravenously, and the number of donor-type CD8α+ DCs arising after 3.5 days was determined. We calculated the per-cell–specific precursor activity and then multiplied this by the number of viable nucleated cells obtained from each donor spleen to give an initial total precursor activity figure for balance sheet purposes (Table 2).

The first step in DC purification involved separating a light-density (less than 1.077 g/cm3) fraction, which included only approximately 5% of the viable nucleated spleen cells but virtually all of the fully developed DCs. Although this fraction gave some enrichment of CD8α+ DC precursor–specific activity (approximately 5-fold), it was less than the 20-fold obtained for DCs. More important, the balance sheet of CD8α+ DC total precursor activity showed that 70% was eliminated with the dense cells (Table 2). Additional studies showed that most of the immediate precursors of CD8α+ DCs were within the 28% of spleen viable nucleated cells, with density ranging between 1.083g/cm3 and 1.077 g/cm3.

Further enrichment of fully developed DCs, by successive immunomagnetic bead depletion of non-DC lineage cells and sorting to remove autofluorescent macrophages, enriched/DC purity to 70% to 80% but gave little further enrichment of CD8+ DC precursor–specific activity (Table 2). The final DC-enriched fraction was only 5-fold enriched in specific CD8α+ precursor activity, and it represented only 11% of the total precursor activity in the original spleen suspension. Much of this apparent activity could have resulted from the seeding and persistence of preformed CD8α+ DCs rather than their generation from precursors. Thus, most of the splenic CD8α+ DC precursors were not CD8α- DCs.

Distribution of CD8α+ DC precursor activity during sorting for CD8α- DCs

Because some apparent CD8α+ DC precursor activity did persist in the DC-enriched fraction, we asked whether CD8α- DCs could be a real, if minor, source of CD8α+ DCs. The enriched fraction (70%-80% DCs) was therefore segregated according to surface expression of the 3 markers used to define CD8α- DCs—CD11c, MHC 2, and CD8α. Labeling the DCs with antibodies to these markers did not result in any loss of CD8α+ DC precursor activity (Table 2). On sorting the labeled cells, precursor activity was found distributed over many fractions (Table 3), not just in the CD8α-, CD11chi, or MHC 2hi fractions. On separation by CD8α expression levels, some “activity” was associated with the CD8α high fraction, and this presumably represented the seeding and persistence of pre-existing CD8α+ DCs. Even more of the total and specific activity was found in the CD8α intermediate fraction, however, suggesting the presence of less mature cells en route to producing CD8α high DCs (Table 3). On separation according to CD11c or MHC 2 expression, the greatest enrichment of activity was in the fractions expressing levels of CD11c and MHC 2 that were lower than those of fully developed DCs and that might therefore contain early DC forms (Table 3). In no case was the precursor activity enriched along with the markers of CD8α- DCs (MHC 2hi, CD11chi, or CD8α-), though some measurable activity was usually associated with these markers, as in Figure 1. When all 3 markers were used together to isolate CD8α-CD11chiMHC 2hi DCs (as in Figure 1), a mean of 1.1% of the total initial spleen precursor activity was recovered in the 3 of 7 experiments when any CD8α+ DCs were found in the recipient spleens (data not shown).

Table 3.

Immediate precursors of CD8α+ DCs in DC-enriched spleen preparations do not segregate with the markers of mature CD8- DCs



Immediate CD8α+ DC precursor activity
Sorted fraction
Specific activity per 106 donor cells
Total activity per donor spleen
CD8α-  172   419  
CD8αint  1059   1231  
CD8αhi  485   478  
CD11c-  738   442  
CD11cint  230   139  
CD11chi  80   263  
MHC 2-  1289   562  
MHC 2int  719   1221  
MHC 2hi
 
147
 
441
 


Immediate CD8α+ DC precursor activity
Sorted fraction
Specific activity per 106 donor cells
Total activity per donor spleen
CD8α-  172   419  
CD8αint  1059   1231  
CD8αhi  485   478  
CD11c-  738   442  
CD11cint  230   139  
CD11chi  80   263  
MHC 2-  1289   562  
MHC 2int  719   1221  
MHC 2hi
 
147
 
441
 

After preparing a DC-enriched preparation, as in Table 2, the preparation was fluorescent-labeled with 1 marker-specific mAb and sorted into fractions negative, intermediate, or high for the chosen marker, eliminating autofluorescent and dead cells in a separate channel. Fully developed CD8α- DCs should be found in the CD8α-, the CD11chi, and the MHC 2hi fractions. Assay for immediate precursor activity and expression of results are as for Table 2. Results represent 3 individual experiments, each typical of 2 such experiments undertaken

In at least some of our experiments, CD8α+CD205+ splenic DCs were generated when purified samples of CD8α- DCs were transferred intravenously, in accordance with the observations of Martinez del Hoyo et al.12  However, our conclusions differ radically from theirs because we demonstrate that most immediate precursors of CD8α+ DCs are not CD8α- DCs at all but are cells lacking the characteristics of mature DCs and so are lost on DC enrichment. Our results highlight the importance of a balance sheet approach, examining activity at all enrichment steps rather than only determining the activity of an enriched candidate cell.

A major limitation of the earlier study was the extremely low recovery of DCs in the spleen following intravenous transfer. We also found this with at most only 0.16% of the sorted CD8α- DCs transferred, forming CD8α+ DCs in the recipient spleens. This poor recovery of DCs after intravenous transfer is compounded by the separate problem of poor recovery of CD8α- DC precursor activity during DC enrichment and purification. When we did recover any CD8α+ DC precursor activity in a highly purified, sorted CD8α-CD11chiMHC 2hi fraction, it represented only 1.1% of the total initial spleen activity. Even allowing for some DC loss during enrichment, this is a very low recovery of activity. However, this final result is in line with the results in Tables 2 and 3, indicating that most CD8α+ DC precursor activity did not segregate with individual markers for the CD8α- fully developed DCs. Although this low-level production from the sorted CD8α- DCs might point to one minor route of CD8α+ DC production, it could also arise from a high-efficiency precursor contaminant. Rather than resolve this issue, we consider future investigation should focus on the major pathways leading to CD8α+ (and CD8α-) DCs.

What, then, are the characteristics of most immediate precursors of the CD8α+ DCs found in normal laboratory mice? We find they are lighter in density than most spleen lymphocytes but more dense than mature DCs, but at present we have little further information. One candidate precursor, the mouse plasmacytoid cell, has recently been eliminated because it produces a subtype of CD8α+ DCs that differs in other markers and that only produces this CD8α+ DC subtype after microbial stimulation.15  Our kinetic studies9,15  indicate that the 3 mature DC subsets and the plasmacytoid cells of normal mouse spleen represent separate development streams at least as far back as the last dividing precursor. However, this may not be very far back, and the separate streams could well branch off from a common DC-committed precursor.16  The relationship between all these DC subtypes and the nature and lineage commitment of their immediate precursors remain to be elucidated.

Prepublished online as Blood First Edition Paper, March 20, 2003; DOI 10.1182/blood-2002-10-3186.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Shortman K, Liu Y-J. Mouse and human dendritic cell subtypes.
Nat Rev Immunol.
2002
;
2
:
153
-163.
2
Wu L, D'Amico A, Hochrein H, Shortman K, Lucas K. Development of thymic and splenic dendritic cell populations from different hemopoietic precursors.
Blood
.
2001
;
98
:
3376
-3382.
3
Manz MG, Traver D, Miyamato T, Weissman IL, Akashi K. Dendritic cell potentials of early lymphoid and myeloid progentitors.
Blood
.
2001
;
97
:
3333
-3341.
4
Aliberti J, Schulz O, Pennington DJ, et al. Essential role for ICSBP in the in vivo development of murine CD8α+ dendritic cells.
Blood
.
2003
;
101
:
305
-310.
5
Guerriero A, Langmuir PB, Spain LM, Scott EW. PU.1 is required for myeloid-derived but not lymphoid-derived dendritic cells.
Blood
.
2000
;
95
:
879
-885.
6
O'Keeffe M, Hochrein H, Vremec D, Pooley J, Evans R, Woulfe S, Shortman K. Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice.
Blood
.
2002
;
99
:
2122
-2130.
7
Wu L, D'Amico A, Winkel KD, Suter M, Lo D, Shortman K. RelB is essential for the development of myeloid-related CD8α- dendritic cells but not of lymphoid-related CD8α+ dendritic cells.
Immunity
.
1998
;
9
:
839
-847.
8
Wu L, Nichogiannopoulou A, Shortman K, Georgopoulos K. Cell-autonomous defects in dendritic cell populations of Ikaros mutant mice point to a developmental relationship with the lymphoid lineage.
Immunity
.
1997
;
7
:
483
-492.
9
Kamath A, Pooley J, O'Keeffe M, et al. The development, maturation and turnover rate of mouse spleen dendritic cell populations.
J Immunol.
2000
;
165
:
6762
-6770.
10
Anjuere F, Martinez del Hoyo G, Martin P, Ardavin C. Langerhans cells acquire a CD8+ dendritic cell phenotype on maturation by CD40 ligation.
J Leukoc Biol.
2000
;
67
:
206
-209.
11
Merad M, Fong L, Bogenberger J, Engleman EG. Differentiation of myeloid dendritic cells into CD8α-positive dendritic cells in vivo.
Blood
.
2000
;
96
:
1865
-1872.
12
Martinez del Hoyo G, Martin P, Arias CF, Marin AR, Ardavin C. CD8α+ dendritic cells originate from the CD8α- dendritic cell subset by a maturation process involving CD8α, DEC-205, and CD24 up-regulation.
Blood
.
2002
;
99
:
999
-1004.
13
Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen.
J Immunol.
2000
;
164
:
2978
-2986.
14
Shortman K. Analytical and preparative equilibrium density separation of lymphoid cells on albumin and metrizamide.
Methods Enzymol.
1984
;
108
:
102
-117.
15
O'Keeffe M, Hochrein H, Vremec D, et al. Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8+ dendritic cells only after microbial stimulus.
J Exp Med.
2002
;
196
:
1307
-1319.
16
Martinez del Hoyo G, Martin P, Vargas HH, Ruiz S, Arias CF, Ardavin C. Characterization of a common precursor population for dendritic cells.
Nature
.
2002
;
415
:
1043
-1047.
Sign in via your Institution